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Abstract.
PURPOSE: The aim of the study was to evaluate the utility of N-terminal pro-B-type natriuretic peptide (NT-pro BNP, pg/ml)
assessment to predict infarct size and left ventricle function after ST-segment elevationmyocardial infarction (STEMI) at long-term
follow-up.
METHODS: In 45 patients with first STEMI less than 3 hours from symptom onset treated with mechanical reperfusion NT-pro
BNP was assessed early (at admission) and at 6 months. Cardiac magnetic resonance (CMR) parameters (delayed enhancement
infarct size (IS, %), left ventricular end-diastolic (LVEDVI, ml/m2) and end-systolic (LVESVI, ml/m2) volume indexes) were
assessed at 6 months.
RESULTS: No significant correlation was found between baseline NT-pro BNP assessment and IS and left ventricle function
after 6 months. There was a significant correlation between 6-month NT-pro BNP and IS (r = 0.65, p < 0.001) and left ventricle
remodeling at 6 months (LVEDVI, r = 0.53, p = 0.001; LVESVI, r = 0.51, p = 0.002).
CONCLUSIONS: Assessment of NT-pro BNP level 6 months after STEMI remains a good indicator of infarct size and left
ventricle function at long-term follow-up.
Keywords: ST-elevation myocardial infarction, infarct size, percutaneous coronary intervention, NT-pro BNP, cardiac magnetic
resonance
1. Introduction
Infarct size is an important prognostic marker with
a strong correlation to mortality after ST-segment ele-
vation myocardial infarction (STEMI) [1,2]. Left ven-
tricular function is strongly related to clinical outcome,
with increasing mortality rates for left ventricular ejec-
tion fraction (LVEF) < 40% [3]. Cardiac magnetic res-
onance (CMR) imaging is the most precise technique
of infarct size assessment with good diagnostic accura-
cy and reproducibility and allows to detect even small
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subendocardial injury [4–6]. The cardiac neurohor-
mone N-terminal pro-B-type natriuretic peptide (NT-
pro BNP) is secreted in response to increased left ven-
tricular wall stretch [7], but also myocardial ischemia
and infarction may stimulate its excretion [8–10]. The
aim of this study was to evaluate the value of NT-pro
BNP in prediction of infarct size and myocardial func-
tion assessed in CMR 6 months after STEMI.
2. Material and methods
2.1. Patient population
The study was approved by the Institutional Review
Board at the Jagiellonian University Medical College
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in Krakow, Poland. All patients gave informed consent
and the study conformed to applicable institutional and
national guidelines for research on human subjects, as
well as to the Declaration of Helsinki. The inclusion
criteria were age over 18 years, STEMI with time from
chest pain onset to diagnosis less than 3 hours. STEMI
was diagnosed if: chest pain persisted over 30 minutes;
there was an ST elevation in J point > 0.2 mV in V2-
V3 and > 0.1 mV in other corresponding leads. Main
exclusion criteria were: lack of informed consent; prior
myocardial infarction; contraindications to lytic ther-
apy; contraindications to PCI (e.g. contrast allergy);
advanced neoplasm or other chronic disease with im-
paired long-term survival; cardiogenic shock; acetyl-
salicylic acid intolerance or contraindications to clopi-
dogrel. All patients received aspirin (300–500 mg),
loading dose of clopidogrel (600 mg), and a bolus of
unfractionated heparin (60–100 U/kg). Tenecteplase
was given in a weight adjusted standard dose in patients
with anticipated delay to PCI longer than 90 minutes.
Before PCI activated clotting time was monitored in
all patients and unfractionated heparin was added if
necessary to maintain optimal anticoagulation. Bare-
metal stents were used during primary PCI. In patients
with multivessel disease PCI was performed only in
the infarct-related artery. Acetylsalicylic acid (75 mg
daily) and clopidogrel (75 mg daily) were prescribed
at discharge for at least 12 months with other drugs ac-
cording to patient individual status and guideline rec-
ommendations for secondary prevention.
2.2. NT-pro BNP analysis
NT-pro BNP was determined in human serum. Sam-
ples of blood were obtained on admission to the cathlab
and after 6 months. The blood sample collected from
the ulnar veinwas centrifugated and stored in a refriger-
ator at−85◦Cuntilfinal examination. Concentration of
NT-pro BNP was determined using automatic Modular
Analytics E170 (Roche) analyzer with electrochemilu-
minescence immunoassay (ECLIA) with two specific
policlonal antibodies against NT-pro BNP.
2.3. Cardiac magnetic resonance
Cardiac magnetic resonance (CMR) study was per-
formed on 1.5T scanner (GE Signa EXCITE) with
TORSOPA coil. Dedicated software was used for
post-processing (MASS, Medis). Analyses were per-
formed by observer blinded to patients’ clinical data.
Left ventricle volumes, LVEF and infarct size in one
Table 1
Characteristics of the study population. Angiography and PCI char-
acteristics (n = 45)
Age (years, median) 60.2 (42–77)
Male (%) 77.6
Diabetes (%) 13.6
Arterial hypertension (%) 53.4
Dyslipidemia (%) 44.4
History of smoking (%) 64.3
Killip class > 1 (%) 11.5
Time from chest pain onset to PCI 223 (87–255)
(minutes, median and IQR)
Infarct related artery (%)
LAD 34.2
Cx 9.5
RCA 56.2
Multivessel disease (%) 21.1
Lytics (%) 48.8
Abciximab (%) 39.1
Stent implantation (%) 93.3
TIMI 3 after PCI (%) 86.3
TMPG 3 after PCI (%) 67.6
Baseline troponin (ng/ml, median and IQR) 0.71 (0.26–1.93)
Baseline CK (IU/l, median and IQR) 359 (165–780)
Baseline CKMB (IU/l, median and IQR) 47 (20–112)
Cx – circumflex artery; IRA – infarct related artery; LAD – left an-
terior descending artery; PCI – percutaneous coronary intervention;
RCA – right coronary artery; TIMI – Thrombolysis In Myocardial
Infarction.
study per patient, minimum 6 months (mean 180 days,
range 170–210 days) after index myocardial infarction
were analyzed. The end-diastolic and end-systolic vol-
ume indices (LVESVI and LVEDVI, ml/m2) were ob-
tained after dividing volume by body surface area ac-
cording to the DuBois formula [11]. Left ventricu-
lar volumes and LVEF were assessed with cine-CMR
using a steady-state free-precession technique (FIES-
TA) with the following imaging parameters: 20 phas-
es per slice location, FOV 32 × 32 cm; TR 1.6 ms;
TE 2.8 ms; FA 20–30◦; matrix 256 × 160; NEX 1.
10–14 consecutive slices of 8 mm were planned in
short axis view. Also one horizontal long axis view
(four-chamber) was obtained. Delayed enhancement
images were acquired 15–20 min after a double bolus
of gadolinium (0.2 mmol/kg) using inversion recovery
gradient-echo sequence with the following imaging pa-
rameters: FOV 42 × 42 cm; TR 8 ms; TE 3.8 ms;
FA 40–50◦, NEX 2; slice thickness 8 mm. The in-
version time was adjusted individually to null normal
myocardium. Slice locations of the delayed enhance-
ment images were copied from the cine images to en-
sure registration between cine-CMR and infarct mea-
surements. The volume of delayed enhancement was
quantified manually from consecutive short axis slices
and was multiplied by 1.05 g/ml to obtain myocardial
infarct mass (1 ml = 1.05 g). Papillary muscles were
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Table 2
Correlations of NTproBNP and infarction size with CK/CKMB/troponin levels at baseline (∗p < 0.05)
CMR infarct size CMR LVEF Baseline NTproBNP 6 months Baseline NTproBNP
CK baseline r = 0.196 (p = 0.28) r = −0.073 (p = 0.68) r = 0.335 (p = 0.049)∗ r = −0.025 (p = 0.89)
CK max r = 0.862 (p < 0.001)∗ r = −0.518 (p = 0.001)∗ r = 0.107 (p = 0.53) r = 0.515 (p = 0.001)∗
CK MB baseline r = 0.182 (p = 0.31) r = −0.103 (p = 0.56) r = 0.313 (p = 0.07) r = −0.035 (p = 0.84)
CK MB max r = 0.830 (p < 0.001)∗ r = −0.488 (p = 0.003)∗ r = 0.090 (p = 0.60) r = 0.483 (p = 0.003)∗
Troponin baseline r = −0.073 (p = 0.70) r = 0.332 (p = 0.07) r = 0.354 (p = 0.06) r = −0.238 (p = 0.20)
Fig. 1. Spearman correlation between NT-pro BNP values at baseline and after 6 months and infarct size.
not included into the delineations of hyperenhanced
area. Infarct size was expressed as percentage of total
left ventricular mass.
3. Statistical analysis
Results were expressed as medians with interquartile
range (IQR) or percentages of patients. Correlations
were calculated using Spearman method with the use
of two-tailed tests. Receiver-operating characteristic
(ROC) curve analysis was performed to calculate sen-
sitivity and specificity of NT-pro BNP value in predict-
ing CMR infarct size after 6 months. Multivariate re-
gression analysis was performed to find significant pre-
dictors of CMR infarct size  10% and CMR LVEF <
40%. Forward selection was used and the probability
value for covariates to enter the model were set at 0.10
level. Following covariates were tested: age, gender,
presence of diabetes mellitus, arterial hypertension, in-
farct related artery (LAD vs. non-LAD), infarct related
artery patency at baseline (TIMI 0 + 1 vs. 2 + 3), time
from symptoms onset to lysis, time from symptoms
onset to balloon. A p value of < 0.05 was considered
statistically significant. Statistica 7.0 (Statsoft, Poland)
was used to perform statistical analysis.
4. Results
A total of 45 patients with STEMI treated with pri-
mary PCI were enrolled. Baseline and angiographic
characteristics are presented in Table 1. In 22 patients
(48.8%) lytic therapy was administered before transfer
to cathlab due to long anticipated delay to PCI. Me-
dian levels of NT-pro BNP at admission were 155.4
(79.2–254) pg/ml,after 6months – 242.2 (108.8–361.3)
pg/ml. The CMR study showed infarct size of 8.1 (4.9–
12.5)%, LVEF of 43.9 (39.2–52.5)%, LVEDVI of 73.4
(62.3–90.9) ml/m2 and LVESVI of 39.5 (29.7–54.4)
ml/m2 (all medians with IQR). There was no correla-
tion between baseline NT-pro BNP and CMR infarct
size (Fig. 1) and left ventricle function at 6 months
(LVEF, r = −0.13, p = 0.5; LVEDVI, r = −0.033,
p = 0.86; LVESVI, r = −0.024, p = 0.9). There was a
significant correlation of NT-pro BNP and CMR infarct
size after 6 months (Fig. 1), LVEDVI (r = 0.52, p =
0.001) and LVESVI (r = 0.54, p = 0.002). We also
found a trend in correlation between NT-pro BNP after
6 months and LVEF assessed in CMR (r = −0.35,
p = 0.08). Correlations of NT-pro BNP and infarct
size with troponin/CK/CKMB levels at baseline were
also calculated (Table 2). In receiver-operating charac-
teristic (ROC) curve analysis, the optimal NT-pro BNP
at 6 months cut-off value to predict CMR infarct size
more than 10% was 134.5 pg/ml with 94% sensitivity
and 69% specificity (AUC = 0.88). The optimal NT-
pro BNP cut-off value was 264.3 pg/ml with 90% sen-
sitivity and 78% specificity (AUC = 0.8) for predicting
LVEF less than 40% at 6 months. The median values
of NT-pro BNP for infarct size less and more/equal
than 10% and LVEF less and more/equal than 40%
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Table 3
Infarct size according to NT-pro BNP median values (median, IQR)
CMR infarct size (%) < 10%  10% p
NT-pro BNP at baseline (pg/ml) 100.7 (66.6–204) 156 (87.1–367.4) 0.24
NT-pro BNP at 6 months (pg/ml) 106.7 (87.5–177.8) 341 (267.4–555.1) < 0.001
Table 4
Left ventricle ejection fraction according to NT-pro BNP median values (median, IQR)
CMR LVEF (%)  40% < 40% p
NT-pro BNP at baseline (pg/ml) 99.2 (74.7.6–197.9) 189.8 (100.3–980) 0.19
NT-pro BNP at 6 months (pg/ml) 137.8 (102–263.1) 195.2 (271.1–630.2) 0.007
Table 5
Multivariate regression analysis for for CMR infarct size  10%
Variable OR (95% CI) P value
NT-pro-BNP 6 months 1.013 (1.001–1.024) 0.029
Age [per 1 year] 0.857 (0.726–1.011) 0.068
IRA patency at baseline [TIMI 2 + 3 vs. 0 + 1] 0.150 (0.001–0.426) 0.014
Table 6
Multivariate regression analysis for LVEF < 40%
Variable OR (95% CI) P value
NT-pro-BNP 6 months 1.006 (1.000–1.013) 0.044
Age [per 1 year] 0.878 (0.752–1.025) 0.099
Infarct-related artery [LAD vs. non-LAD] 9.534 (0.942–96.480) 0.056
are shown in Tables 3 and 4. Results of multivariate
regression analysis are shown in Tables 5 and 6.
5. Discussion
In this study NT-pro BNP assessment at 6 month
was a good indicator of infarct size and left ventricular
function at 6-month follow-up in patients with STE-
MI. Baseline (admission) NT-pro BNP values did not
correlate with any CMR parameters at 6-month. The
reason for this finding could be the enrollment criteria
regarding early presenters with STEMI < 3 hours from
symptom onset and time to PCI 223 minutes (median).
The plasma level of BNP increases rapidly but with-
in hours from the onset of acute myocardial infarction
(AMI) [12]. The CMR examination was performed
after 6 months what allowed to assess infarct zone and
ventricular function in rather stable state of scar evolu-
tion and remodeling process [13]. Very limited data on
BNP and NT-pro BNP and their association with the
extent of myocardial infarct size detected by CMR are
available. Correlations of BNP with infarct size deter-
mined by thallium-201 SPECT [14], technetium-99 m
sestamibi SPECT [15], cardiac enzymes [16,17] and
CMR have been reported previously, nonetheless, only
few studies have focused on the correlation of NT-pro
BNP with infarct size. NT-pro BNP may be superior
to BNP in identifying and evaluating cardiac dysfunc-
tion [18,19] and therefore its correlation with infarct
size andLV function afterAMI. Cochet et al. found cor-
relations between NT-pro BNP concentrations on day
3 after AMI and LVEF and infarct size derived from
the CMR images [20], but they measured NT-pro BNP
in a heterogeneous cohort of patients with acute coro-
nary syndromes and without long-term monitoring. In
our study we analyzed a homogenous group of patients
with STEMI and early presentation up to 3 hours from
symptoms onset. Therefore confounding factors like
clinical variety of acute coronary syndromes, ischaemia
duration, could be eliminated. Haeck et al. investigated
correlation of baseline values of NT-proBNP in pre-
senters below 6 hours from symptom onset with CMR
infarct size 4–6 months after AMI [21]. In contrast to
our study in patients with non-anteriorwall STEMI un-
dergoing primary PCI, an admission NT-pro BNP level
was a strong, independent predictor of left ventricular
function assessed by CMR imaging at follow-up. Mayr
et al. found that NT-pro BNP on day 3 after admis-
sion correlates with acute and chronic infarct size and
LVEF assessed in CMR on day 6 and 12 months af-
ter AMI [22]. The lack of correlation between NT-pro
BNP at baseline and left ventricular function or infarct
size after 6 months might be due to a contribution of
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the ischemic stimulus – resolved later after angioplas-
ty – to an early NT-pro BNP level, which might have
obscured the relationship between NT-pro BNP and LV
hemodynamics [23].
To the best of our knowledge there was no study pre-
viously published demonstrating the relation between
baseline and 6-monthNT-proBNP levels with CMR in-
farct size and CMR left ventricle function after STEMI
in very early presenters (< 3 hours from symptomon-
set).
6. Limitations
Themain limitation of the present study is a relatively
small number of patients enrolled. This allowed only
to analyze surrogate end-points but not clinical end-
points. Only one CMR study was performed for each
patient so it was impossible to observe time changes of
left ventricular parameters.
7. Conclusions
Late assessment of NT-pro BNP is a good indicator
of infarct size and left ventricle function at 6 months in
patients with STEMI.
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